Cost-Effectiveness Analysis of IVF in China: Comprehensive Evaluation of Cost, Success Rate, and Technology

AI Summary

Opening: Real Consultation Scenario

A 32-year-old woman asked me in the clinic: "Doctor, my AMH is 1.8, my total antral follicle count is 9, and my husband's semen is normal. Our annual household income is less than 200,000 RMB. Going to the US would cost 300,000 RMB, and Thailand would also cost over 100,000. Is domestic IVF worth it? Is it really true that you get what you pay for?"

Behind this question is not a simple cost comparison, but a complete understanding of the three words "cost-effectiveness" — in the field of assisted reproduction, cost-effectiveness = (Live Birth Rate × Safety Index) ÷ (Economic Cost + Time Cost + Physical and Mental Toll). Below, we break down this formula from multiple dimensions.

Module A: Direct Answer to the Question

1. Direct Answer on the Cost-Effectiveness of IVF in China

For couples who meet the indications for domestic IVF, the cost-effectiveness of正规 fertility centers in China is at an upper-middle level globally. Specifically:

• Cost Aspect: The total cost for a complete fresh cycle (excluding PGT) ranges from 35,000 to 60,000 RMB, including medication, egg retrieval, embryo culture, transfer, and some tests. If PGT is required, the cycle cost increases to 70,000 to 100,000 RMB.
• Success Rate Aspect: According to data from 2022-2024 from several large domestic fertility centers, the fresh embryo transfer live birth rate for women under 35 is approximately 50%-60%, 35%-45% for ages 36-40, and 15%-25% for women over 40. The cumulative live birth rate (including frozen embryo transfers) is higher.
• Time Cost: From the initial consultation to transfer, it takes about 2-3 months for smooth cases; if multiple egg retrievals are needed or there are complex conditions, the cycle may extend to 6-12 months.

Conclusion: For individuals under 38, without special genetic needs, and with acceptable ovarian reserve, the cost-effectiveness of domestic IVF is significantly better than overseas. However, for advanced maternal age, repeated implantation failure, need for egg donation, or specific genetic testing, the cost-effectiveness needs to be re-evaluated.

Module C: The Doctor's Perspective

2. The Logic of Cost-Effectiveness from a Reproductive Doctor's View

When clinicians evaluate "cost-effectiveness," they don't just look at the single-cycle cost, but focus on "the total medical resources consumed per live birth."

For example: A 38-year-old woman with AMH 1.2. The domestic single-cycle cost is 45,000 RMB. After 2-3 cumulative cycles, the probability of live birth is about 55%-65%, with a total cost of 90,000 to 135,000 RMB. Under the same conditions, the overseas single-cycle cost is 150,000 to 250,000 RMB, also requiring 2-3 cycles, with a total cost of 300,000 to 750,000 RMB. From the doctor's perspective, the cost-effectiveness advantage of domestic treatment for "moderate difficulty" cases is very clear.

However, doctors also point out: Cost-effectiveness is not the only indicator. When domestic policies restrict the availability of certain technologies (such as third-party assisted reproduction in some countries, non-medical sex selection, or broader PGT indications), the high cost overseas corresponds to the value of "technological accessibility."

Module D: Differences Across Age Groups

3. Cost-Effectiveness Differences Across Age Groups

Age is the primary variable affecting the cost-effectiveness of IVF, and the cost-success rate curve differs completely across age groups.

Age Group	Single Cycle Live Birth Rate (Domestic)	Average Number of Cycles Needed	Estimated Total Cost (Domestic)	Cost-Effectiveness Assessment
≤ 35 years	50% ~ 60%	1 ~ 2	40,000 ~ 100,000 RMB	⭐⭐⭐⭐⭐ Extremely High
36 ~ 38 years	40% ~ 50%	2 ~ 3	80,000 ~ 160,000 RMB	⭐⭐⭐⭐ High
39 ~ 41 years	25% ~ 35%	3 ~ 4	140,000 ~ 240,000 RMB	⭐⭐⭐ Moderate
≥ 42 years	10% ~ 20%	4 ~ 6	200,000 ~ 400,000 RMB	⭐⭐ Low (Comprehensive evaluation recommended)

It is clear from the table: The older the age, the more cycles are needed, the total cost rises rapidly, and cost-effectiveness shows a declining trend. For women over 42, the domestic cumulative live birth rate is still significantly lower than the younger group. At this point, the cost-effectiveness advantage weakens, and some patients may consider overseas egg donation or embryo donation programs.

Module F: Differences Between Hospitals

4. The Cost-Effectiveness Gap Between Different Hospitals

The level of domestic fertility centers varies greatly, and the choice of hospital can impact cost-effectiveness by a factor of 2 to 3. The main differences are reflected in:

• Laboratory Conditions: Blastocyst formation rate, frozen-thawed embryo survival rate, and PGT success rate differ significantly between centers. Top centers can achieve a blastocyst formation rate of 60%-70%, while average centers may only reach 40%-50%.
• Degree of Individualization in Clinical Protocols: Experienced fertility centers dynamically adjust stimulation protocols based on AMH, BMI, and previous cycle responses, rather than using a standardized process.
• Multidisciplinary Collaboration: The availability of supporting services such as reproductive immunology, hysteroscopy, genetic counseling, and psychological support affects the cumulative success rate for complex cases.

Module G: Most Easily Overlooked Details

5. Five Most Easily Overlooked Cost-Effectiveness Details

The following factors are often underestimated but can significantly alter the cost-effectiveness calculation:

1. Regional Differences in Examination Costs: Some cities include IVF-related tests in outpatient medical insurance reimbursement (e.g., some items in Beijing, Shanghai), saving 3,000 to 8,000 RMB. Out-of-town patients also need to consider accommodation and lost work costs.
2. Flexibility in Medication Costs: The price difference between imported ovulation induction drugs (e.g., Gonal-f, Puregon) and domestic drugs (e.g., Lishenbao, urinary gonadotropins) is about 30%-50%. For patients with normal ovarian response, domestic drugs offer higher cost-effectiveness.
3. Additional Expenses for Frozen Embryo Transfer Cycles: Many people only calculate the cost of the fresh cycle, ignoring the subsequent costs for endometrial preparation, hormone testing, and transfer surgery in frozen embryo transfer cycles (approximately 8,000 to 15,000 RMB per cycle).
4. Risk of Cycle Cancellation: In some domestic centers, due to a high patient volume, there is a risk of "canceling transfer due to ovarian hyperstimulation" or "canceling the cycle due to arrested embryo development." These hidden costs are not included in the initial quote.
5. Psychological and Time Costs: Frequent leave from work, traveling to and from the hospital, and anxiously waiting for results—these non-economic costs should not be ignored in a high cost-effectiveness evaluation, especially for working individuals.

Module K: Factors Influencing Cost

6. Six Major Factors Influencing the Cost of IVF in China

Factor	Cost Impact Range	Explanation
1. Type of Technology Used	+20,000 ~ +60,000 RMB	IVF (1st generation) is the most basic; ICSI (2nd generation) adds 3,000~5,000 RMB; PGT (3rd generation) adds 20,000~40,000 RMB
2. Choice of Ovulation Induction Medication	+5,000 ~ +18,000 RMB	Imported drugs are 30%-50% more expensive than domestic ones, but some patients respond better to them
3. Hospital Level and Region	+10,000 ~ +30,000 RMB	Top-tier centers in first-tier cities vs. average centers in second- and third-tier cities
4. Need for Ancillary Techniques	+5,000 ~ +20,000 RMB	Assisted hatching, time-lapse embryo imaging, endometrial receptivity testing, etc.
5. Management of Comorbidities	+5,000 ~ +30,000 RMB	Hysteroscopic surgery, immunotherapy, thyroid or metabolic regulation, etc.
6. Number of Repeated Cycles	+35,000~60,000 RMB per cycle	Cumulative cost increases linearly with the number of cycles

Understanding these factors allows for a more accurate estimation of total expenses, avoiding budget deviations caused by "only asking about the single-cycle quote."

Module Q: Frequently Asked Questions

7. Frequently Asked Questions About the Cost-Effectiveness of IVF in China

Question 1: Which has better cost-effectiveness, domestic IVF or IVF in Thailand?

For couples under 35, without special genetic needs, and with normal ovarian reserve, domestic cost-effectiveness is significantly higher—costing only 1/3 to 1/2 of Thailand, with similar success rates. However, for those needing PGT but not meeting domestic indications, or wishing to use third-party assisted reproduction, countries like Thailand offer options not available domestically. In such cases, "cost-effectiveness" needs to incorporate the weight of technological accessibility.

Question 2: With the same 100,000 RMB, doing 2 cycles in China vs. 1 cycle in the US, which has a higher success rate?

For women under 38, the cumulative live birth rate for 2 domestic cycles is about 65%-80%, while 1 cycle in the US is about 50%-65%. The domestic option wins. For women over 42, the cumulative live birth rate for 2 domestic cycles is about 18%-30%, and 1 cycle in the US is about 15%-25%. They are similar, but the domestic cost is lower.

Question 3: Are domestic ovulation induction drugs much less effective than imported ones?

For most patients with normal ovarian reserve (AMH >1.5, antral follicle count >7), there is no statistical difference in the number of eggs retrieved and pregnancy rates between domestic urinary gonadotropins and imported recombinant FSH. However, for patients with poor ovarian response (AMH <1.0) or a history of poor response in previous cycles, imported drugs may provide more stable follicular development, making them more cost-effective.

Question 4: What is the cost-effectiveness of domestic PGT?

Domestic PGT requires clear medical indications (such as chromosomal abnormalities, single gene disorders, recurrent miscarriage, etc.) and costs about 70,000 to 100,000 RMB out-of-pocket. For patients who meet the indications, PGT can significantly reduce the risk of miscarriage and birth defects, offering high cost-effectiveness. However, if done solely to "improve the success rate," there is currently a lack of high-quality evidence to support it, and its cost-effectiveness is questionable.

Module R: Observations from Practitioners

8. Observations from Practitioners: Three Things Beyond Cost-Effectiveness

Having worked in the assisted reproduction industry for over a decade, I have seen many patients overly focused on the two numbers "cost" and "success rate," while ignoring three more fundamental issues:

• ① Physical Condition is a Hard Constraint: For a woman with AMH 0.4, the single-cycle live birth rate will not exceed 15%, whether in China or overseas. Discussing cost-effectiveness at this point is meaningless. The priority should be discussing "whether attempting IVF with own eggs is still necessary" or "whether to consider egg donation."
• ② Policy Boundaries Define the Ceiling of Options: China prohibits non-medical sex selection, commercial egg donation, and surrogacy. If your core needs fall precisely into these three areas, then no matter how high the cost-effectiveness of domestic IVF is, it cannot meet your needs.
• ③ An Institution's "Continuous Quality Improvement" Matters More Than a Single Ranking: A fertility center's success rate from the past year cannot fully predict your personal future outcome. Focusing on the center's SOP, laboratory quality control system, and multidisciplinary consultation capabilities is more valuable than just looking at the advertised "fresh embryo transfer rate."

Conclusion: Doctor's Advice

9. Four Specific Suggestions from Your Doctor

1. Complete a full fertility evaluation before discussing cost-effectiveness: AMH, FSH, antral follicle count, semen analysis, thyroid function, Vitamin D — these basic tests (about 2,000~4,000 RMB) will allow you and your doctor to determine if domestic IVF is suitable for you and roughly how many cycles you might need.
2. Don't just look at the single-cycle price; calculate the "cumulative live birth cost": Ask the hospital clearly: ① The all-inclusive cost of a complete fresh cycle; ② The cost of frozen embryo transfer; ③ The refund policy if a cycle is cancelled. Then, based on your age and ovarian reserve, estimate the total cost for 2-3 cycles.
3. Prioritize centers with annual cycles > 5,000 and independent lab quality control: Centers with a high volume of cycles usually have advantages in operational proficiency, lab stability, and protocol individualization. These "soft strengths" will directly impact your cumulative success rate.
4. If you are > 40 years old or have AMH < 1.0, consider consulting 2-3 centers both domestically and internationally: The cost-effectiveness evaluation for this group is more complex and requires an individualized decision based on specific hormone levels, medical history, financial budget, and psychological resilience. Do not make a judgment based on a single source of information.

A final reminder: IVF is not about "getting a bargain." The true meaning of cost-effectiveness is to choose a path with the highest probability of live birth and the least physical and mental toll, within the economic and time constraints you can bear. China's assisted reproductive technology is already at the forefront internationally in terms of clinical scale and basic capabilities. For most families meeting domestic indications, it is indeed a highly cost-effective path. However, everyone's fertility situation is unique. Before making a decision, be sure to obtain your complete examination reports and have an in-depth consultation with a reproductive doctor lasting no less than 30 minutes.